Abdominal Obesity
Conditions
Interventions
37°C Moxibustion + Lifestyle Intervention:The patient assumes a supine position with full-body relaxation.A moxa stick is ignited at one end and held on Zhongwan (CV12),Shenque (CV8),Bilateral Zusanl
Personalized calorie and nutrient adjustments based on metabolic needs
Structured aerobic and resistance training programs.
43°C Moxibustion + Lifestyle Intervention:The patient assumes a supine position with full-body relaxation.A moxa stick is ignited at one end and held on Zhongwan (CV12)Shenque (CV8)Bilateral Zusanli
Sponsors
Hubei University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Diagnostic Criteria for Abdominal Obesity According to the Guidelines for the Diagnosis and Treatment of Obesity (2024 Edition) issued by the National Health Commission of the People's Republic of China the diagnostic criteria for abdominal obesity are: Men: Waist circumference =90 cm Women: Waist circumference =85 cm Inclusion Criteria: (1)Meeting the above diagnostic criteria for abdominal obesity; (2)Aged 18–65 years (gender unrestricted); (3)Voluntarily participating in the clinical trial with signed informed consent. Those who meet the above three articles at the same time can only be included.
Exclusion criteria
Exclusion criteria: (1)Severe endocrine disorders (e.g. hypothyroidism Cushings syndrome); (2)Clinically diagnosed eating disorders (e.g. bulimia nervosa hyperphagia anorexia nervosa) or weight fluctuation >5 kg within the past 3 months; (3)History of bariatric surgery; (4)Participation in other weight-loss clinical trials within 3 months or current use of drug/diet/exercise interventions for weight management; (5)Use of medications affecting weight/appetite within 3 months including:Anti-obesity drugsCorticosteroidsAntidepressantsBenzodiazepinesNon-selective systemic antihistaminesNicotine replacement therapyHypoglycemic agents; (6)Poorly controlled comorbidities:Cardiovascular diseasesHepatic/renal dysfunctionAcute infectionsAdvanced malignancies; (7)Any medical/psychiatric condition (e.gcognitive impairment intellectual disability) that may increase risks or compromise trial participation (per investigators judgment); (8)Pregnancy lactation menopause or planned pregnancy within 8 weeks; (9)Local skin lesions (ulcers infections or severe dermatological diseases) at treatment sites; (10)Allergy to moxa smoke or keloid predisposition; (11)TCM syndromes of yin deficiency with fire effulgence or excess heat; (12)Current enrollment in other clinical trials; (13)Moxibustion treatment within 3 months; (14)Poor compliance (inability to adhere to the protocol). Patients meeting any of the above criteria will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Waist Circumference; | — |
Secondary
| Measure | Time frame |
|---|---|
| Body Fat Percentage (F%);weight;Chinese visceral adiposity index,CVAI;Beck Depression Inventory-II ;Fasting Plasma Glucose (FPG), Fasting Insulin (FINS),Standard Lipid Panel;Homeostatic Model Assessment of Insulin Resistance (HOMA-IR);Waist-to-hip ratio;BMI;waist-height ratio;Hip Circumference ;Generalized Anxiety Disorder 7-item scale (GAD-7); | — |
Countries
China
Contacts
Public ContactZhou Zhongyu
First Clinical Medical College of Hubei University of Chinese Medicine
Outcome results
None listed